Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13182MR)

This product GTTS-WQ13182MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Acute myeloid leukemia (AML), Solid tumors research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, PF-04518600(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13182MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15993MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ14148MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ1604MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACE-536
GTTS-WQ14028MR IVTScrip™ mRNA-Anti-LAG3, aLAG367(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aLAG367
GTTS-WQ3099MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA APG-101
GTTS-WQ7271MR IVTScrip™ mRNA-Anti-VEGFA, FP3 protein(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FP3 protein
GTTS-WQ11756MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ587MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW